laninamivir octanoate hydrate
Small moleculeexperimental
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00311714)
Timeline
Indications
Studied for
Mechanism of action
- NeuraminidaseINHIBITOR
Neuraminidase inhibitor
- NeuraminidaseINHIBITOR
Neuraminidase inhibitor
- NeuraminidaseINHIBITOR
Neuraminidase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@H]([C@@H]1OC(C(=O)O)=C[C@H](NC(=N)N)[C@H]1NC(C)=O)[C@H](O)CO- Mol. weight
- 346.34 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL467058 ↗
- ChEMBLCHEMBL466246 ↗
Also known as
- cs8958
- cs 8958
- cs-8958
- cs-8958
- cs-8958
- cs-8958
- inavir
- laninamivir
- laninamivir
- laninamivir octanoate
- laninamivir octanoate
- laninamivir octanoate
- laninamivir octanoate
- laninamivir octanoate
- laninamivir octanoate hydrate
- laninamivir octanoate hydrate
- laninamivir octanoate hydrate
- laninamivir octanoate hydrate
- laninamivir octanoate hydrate
- r125489
- r 125489
- r-125489
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05648448 | Phase 2 | Dec 22, 2022 | University of Oxford |
| NCT02014649 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2013 | Aviragen Therapeutics, Department of Health and Human Services |
| NCT02022761 | Phase 1 | Oct 1, 2013 | Aviragen Therapeutics, Department of Health and Human Services |
| NCT01793883 | Phase 2 | May 1, 2013 | Aviragen Therapeutics, Department of Health and Human Services |
| NCT00995826 | Phase 1 | Apr 1, 2009 | Aviragen Therapeutics, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00803595 | Phase 3 | Nov 1, 2008 | Daiichi Sankyo |
| NCT00657111 | Phase 1 | Apr 1, 2008 | Aviragen Therapeutics, Covance, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00311714 | Phase 1 | Apr 1, 2007 | Aviragen Therapeutics, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aviragen Therapeutics | For profit | 6 | 6 | 2 | 2007 |
| Department of Health and Human Services | Government | 3 | 0 | 2 | 2013 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 0 | 1 | 2007 |
| Covance | For profit | 1 | 0 | 1 | 2008 |
| Daiichi Sankyo | For profit | 1 | 1 | 1 | 2008 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2022 |
6 organizations
Page 1 / 1